General Information of Drug (ID: DM3DIW9)

Drug Name
1,2,4-triazole [4,3-a]quinoxaline derivative 2 Drug Info
Synonyms PMID27321640-Compound-34
Cross-matching ID
PubChem CID
60151243
TTD Drug ID
DM3DIW9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tofisopam DMTGNWU Hyperuricaemia 5C55.Y Phase 2 [2]
CP-461 DMEYMTX Inflammatory bowel disease DD72 Phase 2 [3]
ND7001 DMUBTC6 Mood disorder 6A60-6E23 Phase 1 [4]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 DMC8935 N. A. N. A. Patented [1]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2 DM4CSBD N. A. N. A. Patented [1]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2 DMS3ROL N. A. N. A. Patented [1]
Triazolo-pyridine derivative 5 DM1R205 N. A. N. A. Patented [1]
PMID27321640-Compound-58 DM0NYK3 N. A. N. A. Patented [1]
Triazolo-pyridine derivative 4 DM5ZQKS N. A. N. A. Patented [1]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 3 DMZ61T8 N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tofisopam DMTGNWU Hyperuricaemia 5C55.Y Phase 2 [2]
TAK-063 DMP1873 Schizophrenia 6A20 Phase 2 [5]
PF-02545920 DMJPE61 Huntington disease 8A01.10 Phase 2 [6]
OMS824 DMA4OGL Huntington disease 8A01.10 Phase 2 [7]
Lu AF11167 DMJOYNZ Schizophrenia 6A20 Phase 2 [8]
FRM-6308 DMNCOE1 Schizophrenia 6A20 Phase 1b [9]
PBF-999 DMBSQH9 Huntington disease 8A01.10 Phase 1 [10]
RG7203 DMYX4NP Schizophrenia 6A20 Phase 1 [11]
AMG 579 DMRMC7U Schizophrenia 6A20 Phase 1 [12]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 DMC8935 N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 10A (PDE10) TTJW4LU PDE10_HUMAN Inhibitor [1]
Phosphodiesterase 2A (PDE2A) TTJGW1Z PDE2A_HUMAN Inhibitor [1]

References

1 Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
2 The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
3 Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs. 2001 May;2(5):677-83.
4 Phosphodiesterase 2 inhibitors promote axonal outgrowth in organotypic slice co-cultures. Neurosignals. 2013;21(3-4):197-212.
5 Characterization of Binding and Inhibitory Properties of TAK-063, a Novel Phosphodiesterase 10A Inhibitor. PLoS One. 2015; 10(3): e0122197.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 New Drugs/Drug News. P T. 2013 November; 38(11): 667-672.
8 PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action?. Front Neurosci. 2021 Jan 20;14:600178.
9 Massive schizophrenia genomics study offers new drug directions. Nat Rev Drug Discov. 2014 Sep;13(9):641-2.
10 Clinical pipeline report, company report or official report of Palobiofarma.
11 Synaptic synopsis. SciBX 6(41); doi:10.1038/scibx.2013.1153. Oct. 24, 2013
12 Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase10A (PDE10A). J Med Chem. 2014 Aug 14;57(15):6632-41.